Prescription Drug Affordability Board frustrated by slow progress of cost-reduction efforts

Members of Maryland’s Prescription Drug Affordability Board expressed frustration Monday on the slow pace of the so-called “cost review” process to determine if six prescription drugs are unaffordable for workers on state health plans. While most of the administrative hurdles have been addressed, staff said it could still take months before the board is at a point where it can officially declare whether a half-dozen medications are unaffordable for Marylanders.